MX2016011384A - Metodo para tratar la depresion y el trastorno depresivo mayor. - Google Patents
Metodo para tratar la depresion y el trastorno depresivo mayor.Info
- Publication number
- MX2016011384A MX2016011384A MX2016011384A MX2016011384A MX2016011384A MX 2016011384 A MX2016011384 A MX 2016011384A MX 2016011384 A MX2016011384 A MX 2016011384A MX 2016011384 A MX2016011384 A MX 2016011384A MX 2016011384 A MX2016011384 A MX 2016011384A
- Authority
- MX
- Mexico
- Prior art keywords
- gene
- individual
- provides methods
- depression
- determining
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000024714 major depressive disease Diseases 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 102100028284 Collagen alpha-1(XXVI) chain Human genes 0.000 abstract 2
- 102100021242 Dymeclin Human genes 0.000 abstract 2
- 101710081222 Dymeclin Proteins 0.000 abstract 2
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 abstract 2
- 101000860862 Homo sapiens Collagen alpha-1(XXVI) chain Proteins 0.000 abstract 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 abstract 2
- 101000785573 Homo sapiens Zinc finger and SCAN domain-containing protein 4 Proteins 0.000 abstract 2
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 abstract 2
- 102100026569 Zinc finger and SCAN domain-containing protein 4 Human genes 0.000 abstract 2
- 102100034649 Zinc finger protein 551 Human genes 0.000 abstract 2
- 101710143392 Zinc finger protein 551 Proteins 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 abstract 2
- 229960002263 vortioxetine Drugs 0.000 abstract 2
- 101150117138 FOXL2NB gene Proteins 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948529P | 2014-03-05 | 2014-03-05 | |
| US201462061417P | 2014-10-08 | 2014-10-08 | |
| PCT/US2015/018701 WO2015134585A1 (en) | 2014-03-05 | 2015-03-04 | Method for treating depression and major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011384A true MX2016011384A (es) | 2017-05-01 |
Family
ID=54055831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011384A MX2016011384A (es) | 2014-03-05 | 2015-03-04 | Metodo para tratar la depresion y el trastorno depresivo mayor. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170137880A1 (https=) |
| EP (1) | EP3114239A4 (https=) |
| JP (1) | JP2017512204A (https=) |
| KR (1) | KR20160127126A (https=) |
| CN (1) | CN106536751A (https=) |
| AU (1) | AU2015227296A1 (https=) |
| CA (1) | CA2940683A1 (https=) |
| IL (1) | IL247379A0 (https=) |
| MA (1) | MA39485A (https=) |
| MX (1) | MX2016011384A (https=) |
| RU (1) | RU2016138574A (https=) |
| WO (1) | WO2015134585A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087735A1 (en) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Method for treating crohn's disease |
| US20190216803A1 (en) | 2017-03-30 | 2019-07-18 | Rundle Research, LLC | Methods of treating depression with vortioxetine |
| DK3528811T3 (da) * | 2017-03-30 | 2021-09-27 | Rundle Res Llc | Vortioxetin og mao-inhibitorer til behandling af depression |
| EP3909600A1 (en) * | 2020-05-12 | 2021-11-17 | International Centre For Genetic Engineering And Biotechnology - ICGEB | Emid2 protein as anti-cancer treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044043B2 (en) * | 2006-06-16 | 2021-03-03 | H. Lundbeck A/S | 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| EP2581453A3 (en) * | 2008-01-17 | 2013-07-10 | Suregene Llc | Genetic Markers of Mental Illness |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| US20130274133A1 (en) * | 2010-10-01 | 2013-10-17 | Rigshospitalet | Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors |
| WO2012109565A1 (en) * | 2011-02-10 | 2012-08-16 | Neurotherics, Llc | Genetic identification of response to antidepressant medications |
| US9243464B2 (en) * | 2011-02-10 | 2016-01-26 | Baker Hughes Incorporated | Flow control device and methods for using same |
| KR102035877B1 (ko) * | 2011-11-14 | 2019-10-23 | 알파시그마 에스.피.에이. | 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법 |
-
2015
- 2015-03-04 JP JP2016554883A patent/JP2017512204A/ja active Pending
- 2015-03-04 EP EP15758563.9A patent/EP3114239A4/en not_active Withdrawn
- 2015-03-04 RU RU2016138574A patent/RU2016138574A/ru not_active Application Discontinuation
- 2015-03-04 WO PCT/US2015/018701 patent/WO2015134585A1/en not_active Ceased
- 2015-03-04 KR KR1020167027125A patent/KR20160127126A/ko not_active Withdrawn
- 2015-03-04 CN CN201580023401.1A patent/CN106536751A/zh active Pending
- 2015-03-04 AU AU2015227296A patent/AU2015227296A1/en not_active Abandoned
- 2015-03-04 CA CA2940683A patent/CA2940683A1/en not_active Abandoned
- 2015-03-04 MX MX2016011384A patent/MX2016011384A/es unknown
- 2015-03-04 US US15/123,072 patent/US20170137880A1/en not_active Abandoned
- 2015-03-04 MA MA039485A patent/MA39485A/fr unknown
-
2016
- 2016-08-21 IL IL247379A patent/IL247379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160127126A (ko) | 2016-11-02 |
| EP3114239A1 (en) | 2017-01-11 |
| MA39485A (fr) | 2015-09-11 |
| EP3114239A4 (en) | 2017-10-11 |
| WO2015134585A1 (en) | 2015-09-11 |
| US20170137880A1 (en) | 2017-05-18 |
| RU2016138574A (ru) | 2018-04-06 |
| CA2940683A1 (en) | 2015-09-11 |
| IL247379A0 (en) | 2016-11-30 |
| JP2017512204A (ja) | 2017-05-18 |
| AU2015227296A1 (en) | 2016-09-08 |
| RU2016138574A3 (https=) | 2018-10-12 |
| CN106536751A (zh) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502724A1 (en) | Compositions for modulating c9orf72 expression | |
| ZA201802351B (en) | Electrode system, device and method for the treatment of eye diseases, in particular dry eye | |
| EP3562494A4 (en) | GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS | |
| GB201418007D0 (en) | Animal skin substrate Treatment apparatus and method | |
| GB201418006D0 (en) | Animal skin substrate treatment apparatus and method | |
| ZA201901542B (en) | Use of collagen hydrolysate for improving endurance performance and for stimulating lipocatabolism | |
| EP3250240A4 (en) | Dimeric collagen hybridizing peptides and methods of using | |
| IL272121A (en) | Preparation and methods for the treatment of myopia | |
| EP3187579A4 (en) | Composition, support, wastewater treatment system, wastewater treating method, deodorization method, and batch wastewater treating method | |
| GB2552297B (en) | Liquid treatment apparatus, distillation apparatus, and method of distillation | |
| EP3595634A4 (en) | CONSTRUCTIONS FOR GENE THERAPY AND METHODS FOR THE TREATMENT OF HEARING LOSS | |
| PL3570983T3 (pl) | System, zabiegi i aparatura do pielęgnacji włosów | |
| EP3226752A4 (en) | Electrode placement and treatment system and method of use thereof | |
| EP3076985C0 (en) | COMPOSITION COMPRISING PROBIOTICS CAPABLE OF OVEREXPRESSING CLPB PROTEIN FOR USE IN THE TREATMENT OF OBESITY | |
| SG11202007546YA (en) | Water treatment apparatus, water treatment method, and method of starting water treatment apparatus | |
| MX2016011384A (es) | Metodo para tratar la depresion y el trastorno depresivo mayor. | |
| EP4480577A3 (en) | Structured elements and methods of use | |
| IL248080A0 (en) | System and method for identifying sources associated with biological arrhythmias | |
| EP3309129A4 (en) | Electrolysis device, and water treatment method | |
| IL274363B1 (en) | Use of a specific anti-protein siRNA for the treatment of hemophilia | |
| ZA201904328B (en) | Composition, application thereof and treatment method | |
| IL271727A (en) | Method of treatment and their dosage forms | |
| EP3496742A4 (en) | PEPTICORPS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING EAR FIBRILLATION | |
| ZA201902097B (en) | Inducer for regeneration of bone and soft tissue, and method for making same and uses thereof | |
| GB201710491D0 (en) | Composition and methods of treatment |